Ignite Creation Date:
2025-12-25 @ 3:00 AM
Ignite Modification Date:
2026-03-03 @ 2:26 PM
Study NCT ID:
NCT03349333
Status:
COMPLETED
Last Update Posted:
2019-10-01
First Post:
2016-07-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D016411', 'term': 'Lymphoma, T-Cell, Peripheral'}, {'id': 'D016399', 'term': 'Lymphoma, T-Cell'}], 'ancestors': [{'id': 'D008228', 'term': 'Lymphoma, Non-Hodgkin'}, {'id': 'D008223', 'term': 'Lymphoma'}, {'id': 'D009370', 'term': 'Neoplasms by Histologic Type'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008232', 'term': 'Lymphoproliferative Disorders'}, {'id': 'D008206', 'term': 'Lymphatic Diseases'}, {'id': 'D006425', 'term': 'Hemic and Lymphatic Diseases'}, {'id': 'D007160', 'term': 'Immunoproliferative Disorders'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C418863', 'term': '10-propargyl-10-deazaaminopterin'}, {'id': 'D014805', 'term': 'Vitamin B 12'}, {'id': 'D005492', 'term': 'Folic Acid'}], 'ancestors': [{'id': 'D045728', 'term': 'Corrinoids'}, {'id': 'D045725', 'term': 'Tetrapyrroles'}, {'id': 'D011758', 'term': 'Pyrroles'}, {'id': 'D001393', 'term': 'Azoles'}, {'id': 'D006573', 'term': 'Heterocyclic Compounds, 1-Ring'}, {'id': 'D006571', 'term': 'Heterocyclic Compounds'}, {'id': 'D006576', 'term': 'Heterocyclic Compounds, 4 or More Rings'}, {'id': 'D000072471', 'term': 'Heterocyclic Compounds, Fused-Ring'}, {'id': 'D047028', 'term': 'Macrocyclic Compounds'}, {'id': 'D011083', 'term': 'Polycyclic Compounds'}, {'id': 'D011622', 'term': 'Pterins'}, {'id': 'D011621', 'term': 'Pteridines'}, {'id': 'D006574', 'term': 'Heterocyclic Compounds, 2-Ring'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'guodong.lu@mundipharma.com.cn', 'phone': '8610-65636856', 'title': 'clinical study manager', 'organization': 'Mundipharma(China) Co.,Ltd'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'AEs were recorded in the eCRF from the point at which the ICF was signed until 30 (± 5) days after the last dose of pralatrexate. This included new AEs that were reported in the 30 (± 5) days after the last dose of pralatrexate.', 'eventGroups': [{'id': 'EG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.', 'otherNumAtRisk': 71, 'deathsNumAtRisk': 71, 'otherNumAffected': 70, 'seriousNumAtRisk': 71, 'deathsNumAffected': 29, 'seriousNumAffected': 35}], 'otherEvents': [{'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 101, 'numAffected': 48}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 50, 'numAffected': 22}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Lung infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 8, 'numAffected': 7}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Platelet count decreased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 13, 'numAffected': 10}], 'organSystem': 'Investigations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Thrombocytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 4, 'numAffected': 4}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Pneumonia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 5, 'numAffected': 4}], 'organSystem': 'Infections and infestations', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Febrile neutropenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 3, 'numAffected': 3}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Pancytopenia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 2, 'numAffected': 2}], 'organSystem': 'Blood and lymphatic system disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Hepatic function abnormal', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}, {'term': 'Liver injury', 'stats': [{'groupId': 'EG000', 'numAtRisk': 71, 'numEvents': 1, 'numAffected': 1}], 'organSystem': 'Hepatobiliary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '5'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Objective Response Rate(ORR) by International Working Group Criteria', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'categories': [{'measurements': [{'value': '37', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': '2 years', 'description': 'ORR defined as the percentage of subjects with CR, CRu or PR as Best Overall Response.Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (i.e. prior to cycles 6, 8, etc). Unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.The primary analysis will be conducted once all subjects have completed cycle 5 treatment or discontinued before. Study treatment may continue per investigator judgment for a maximum of 24 months.\n\nResponse will be assessed on the basis of clinical, radiological, and pathological criteria. Response will be assessed by independent central review and by the treating investigator. Central review assessors will be blinded to the response assessments by the treating investigator. The primary analysis will be based on response assessed by central review.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The primary analysis was based on the independent review data using the safety population, safety population is 71 for this study'}, {'type': 'SECONDARY', 'title': 'Time to Response (TTR)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.0947', 'spread': '1.6590', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '2 years', 'description': 'Time to response was measured from first day of treatment to the first date of documented response.', 'unitOfMeasure': 'months', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'The secondary analyses was performed using the safety population and repeated using the per-protocol population.'}, {'type': 'SECONDARY', 'title': 'Progression-Free Survival (PFS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'categories': [{'measurements': [{'value': '4.76', 'groupId': 'OG000', 'lowerLimit': '3.06', 'upperLimit': '8.75'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '2 years', 'description': 'PFS was measured from treatment day 1 until event or censoring. An event was defined as the earliest of the following: death from any cause or disease progression. Subjects undergoing transplant or any other subsequent therapy prior to documentation of PD was censored at that time. Progression of disease deems as 1. 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders, 2.Appearance of any new lesion during or at the end of therapy as per IWC criteria.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The secondary analyses was performed using the safety population and repeated using the per-protocol population.'}, {'type': 'SECONDARY', 'title': 'Overall Survival (OS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'categories': [{'measurements': [{'value': '18.00', 'comment': 'This analysis is based on cut off data, there are no enough events to estimated upper limit of 95% CI of median OS.', 'groupId': 'OG000', 'lowerLimit': '10.35', 'upperLimit': 'NA'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '4 years', 'description': 'OS was measured from treatment day 1 until death or censoring.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The secondary analyses was performed using the safety population and repeated using the per-protocol population.'}, {'type': 'SECONDARY', 'title': 'Duration of Responses', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'categories': [{'measurements': [{'value': '8.67', 'groupId': 'OG000', 'lowerLimit': '3.32', 'upperLimit': '14.13'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': '4 years', 'description': 'Duration of response was measured from first day of documented response to disease progression or death, whatever comes first.', 'unitOfMeasure': 'months', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'The secondary analyses was performed using the safety population and repeated using the per-protocol population.'}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Treatment Emergent Adverse Events', 'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'categories': [{'measurements': [{'value': '98.6', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': '4 years', 'description': 'treatment emergent AE was scheduled to be collected during all subject visits, the data evaluated as clinical significant will be summarized and presented.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': 'safety population'}, {'type': 'SECONDARY', 'title': 'Area Under the Curve [AUC] for R-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-R in Cycle 1 week 6（20mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2350.7402', 'spread': '28.22', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R in Cycle 1 week 6（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3979.1069', 'spread': '152.16', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R in Cycle 1 day 1（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3586.2925', 'spread': '43.70', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Cycle 1 day1，Cycle 1 week 6(Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection)', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'h*ng/ml', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'Based on PK population'}, {'type': 'SECONDARY', 'title': 'Area Under the Curve [AUC] for S-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-S in Cycle 1 week 6（20mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1364.7686', 'spread': '22.65', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S in Cycle 1 week 6（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2182.5078', 'spread': '264.05', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S in Cycle 1 day 1（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1674.8773', 'spread': '38.32', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'h*ng/ml', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Steady State Volume of Distribution [Vdss] for R-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-R Cycle 1 day1（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '194.1589', 'spread': '87.4028', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R Cycle 1 week6（20mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '344.2511', 'spread': '109.8671', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R Cycle 1 week6（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '329.1892', 'spread': '251.4938', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week6(Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection)', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Steady State Volume of Distribution [Vdss] for S-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-S Cycle 1 Day 1 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '517.1628', 'spread': '292.2888', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S Cycle 1 Week 6 (20 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1110.6541', 'spread': '548.2687', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S Cycle 1 Week 6 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '1680.6116', 'spread': '2292.0216', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'L', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Steady State Clearance [CLss] for R-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-R Cycle 1 Day 1 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '17.1914', 'spread': '6.7903', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R Cycle 1 Week 6 (20 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '16.3789', 'spread': '5.3859', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R Cycle 1 Week 6 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '19.8406', 'spread': '8.9265', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'L/h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Steady State Clearance [CLss] for S-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-S Cycle 1 Day 1 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '34.6341', 'spread': '17.9816', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S Cycle 1 Week 6 (20 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '27.9794', 'spread': '8.4317', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S Cycle 1 Week 6 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '45.2022', 'spread': '22.4576', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'L/h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Maximum Observed Plasma Concentration [Cmax] for R-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-R in Cycle 1 day 1（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '4649.6811', 'spread': '83.74', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R in Cycle 1 week 6（20mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2488.1502', 'spread': '17.78', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R in Cycle 1 week 6（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '5064.6667', 'spread': '421.48', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Maximum Observed Plasma Concentration [Cmax] for S-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-S in Cycle 1 day 1（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3727.8582', 'spread': '118.25', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S in Cycle 1 week 6（20mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '2325.5105', 'spread': '24.22', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S in Cycle 1 week 6（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '3439.9695', 'spread': '697.55', 'groupId': 'OG000'}]}]}], 'paramType': 'GEOMETRIC_MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'ng/mL', 'dispersionType': 'Geometric Coefficient of Variation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Time of Cmax Observation [Tmax] for R-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-R in Cycle 1 day 1（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1000', 'groupId': 'OG000', 'lowerLimit': '0.067', 'upperLimit': '0.333'}]}]}, {'title': 'Pralatrexate-R in Cycle 1 week 6（20mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1000', 'groupId': 'OG000', 'lowerLimit': '0.100', 'upperLimit': '0.167'}]}]}, {'title': 'Pralatrexate-R in Cycle 1 week 6（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1000', 'groupId': 'OG000', 'lowerLimit': '0.067', 'upperLimit': '0.250'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'h', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Time of Cmax Observation [Tmax] for S-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-S in Cycle 1 day 1（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1000', 'groupId': 'OG000', 'lowerLimit': '0.067', 'upperLimit': '0.333'}]}]}, {'title': 'Pralatrexate-S in Cycle 1 week 6（20mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1000', 'groupId': 'OG000', 'lowerLimit': '0.100', 'upperLimit': '0.167'}]}]}, {'title': 'Pralatrexate-S in Cycle 1 week 6（30mg/m2）', 'denoms': [{'units': 'Participants', 'counts': [{'value': '9', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '0.1000', 'groupId': 'OG000', 'lowerLimit': '0.067', 'upperLimit': '0.250'}]}]}], 'paramType': 'MEDIAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'h', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Terminal Phase Half-life [t1/2Z] for R-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-R Cycle 1 Day 1 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '14', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '8.5040', 'spread': '3.4927', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R Cycle 1 Week 6 (20 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '14.6089', 'spread': '0.1970', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-R Cycle 1 Week 6 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '8', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '11.8249', 'spread': '4.3282', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}, {'type': 'SECONDARY', 'title': 'Terminal Phase Half-life [t1/2Z] for S-pralatrexate', 'denoms': [{'units': 'Participants', 'counts': [{'value': '15', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'classes': [{'title': 'Pralatrexate-S Cycle 1 Day 1 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '10.8634', 'spread': '5.6517', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S Cycle 1 Week 6 (20 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '3', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '26.2505', 'spread': '7.7381', 'groupId': 'OG000'}]}]}, {'title': 'Pralatrexate-S Cycle 1 Week 6 (30 mg/m2)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '7', 'groupId': 'OG000'}]}], 'categories': [{'measurements': [{'value': '24.8987', 'spread': '23.2607', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.', 'unitOfMeasure': 'h', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'PK population'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '71'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '71'}]}], 'dropWithdraws': [{'type': 'Progression of Disease', 'reasons': [{'groupId': 'FG000', 'numSubjects': '36'}]}, {'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '11'}]}, {'type': 'Other', 'reasons': [{'groupId': 'FG000', 'numSubjects': '6'}]}, {'type': 'Withdrawal by Subject', 'reasons': [{'groupId': 'FG000', 'numSubjects': '5'}]}, {'type': 'Conditions interfere with participation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}]}, {'type': 'Physician Decision', 'reasons': [{'groupId': 'FG000', 'numSubjects': '2'}]}, {'type': '3-week lapse between pralatrexate doses', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}]}, {'type': 'Patients in treatment less than 24 month', 'reasons': [{'groupId': 'FG000', 'numSubjects': '8'}]}]}], 'preAssignmentDetails': 'In the protocol, 85 patients are planned to enroll. However, 71 patients are treated in the real situation.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '71', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'PTCL Subtype', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate\n\npralatrexate: Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.\n\nVitamin B12 and folic acid: The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'title': 'Age(years)', 'categories': [{'measurements': [{'value': '54.5', 'spread': '12.52', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '24', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '47', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Asian', 'measurements': [{'value': '71', 'groupId': 'BG000'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Black or African American', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'White', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'China', 'categories': [{'measurements': [{'value': '71', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'calculatePct': False, 'unitOfMeasure': 'Participants'}, {'title': 'Baseline Characteristics', 'classes': [{'title': 'Subtype of PTCL from investigator', 'categories': [{'title': 'PTCL not otherwise specified (NOS)', 'measurements': [{'value': '34', 'groupId': 'BG000'}]}, {'title': 'Angioimmunoblastic T-cell lymphoma', 'measurements': [{'value': '19', 'groupId': 'BG000'}]}, {'title': 'Anaplastic large cell lymphoma, ALK+', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'Anaplastic large cell lymphoma, ALK-', 'measurements': [{'value': '7', 'groupId': 'BG000'}]}, {'title': 'Extranodal NK/T-cell lymphoma - nasal type', 'measurements': [{'value': '5', 'groupId': 'BG000'}]}, {'title': 'Subcutaneous panniculitis-like T-cell lymphoma', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'Enteropathy-associated T cell lymphoma', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Adult T-cell lymphoma/leukemia (human T-cell leuke', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'other', 'measurements': [{'value': '0', 'groupId': 'BG000'}]}]}, {'title': 'Subtype of PTCL from central review', 'categories': [{'title': 'PTCL not otherwise specified (NOS)', 'measurements': [{'value': '34', 'groupId': 'BG000'}]}, {'title': 'Angioimmunoblastic T-cell lymphoma', 'measurements': [{'value': '20', 'groupId': 'BG000'}]}, {'title': 'Anaplastic large cell lymphoma, ALK+', 'measurements': [{'value': '2', 'groupId': 'BG000'}]}, {'title': 'Anaplastic large cell lymphoma, ALK-', 'measurements': [{'value': '6', 'groupId': 'BG000'}]}, {'title': 'Extranodal NK/T-cell lymphoma - nasal type', 'measurements': [{'value': '5', 'groupId': 'BG000'}]}, {'title': 'Subcutaneous panniculitis-like T-cell lymphoma', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Enteropathy-associated T cell lymphoma', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'Adult T-cell lymphoma/leukemia (human T-cell leuke', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}, {'title': 'other', 'measurements': [{'value': '1', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'Safety population is 71'}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2015-04-03', 'size': 2006830, 'label': 'Study Protocol', 'hasIcf': False, 'hasSap': False, 'filename': 'Prot_000.pdf', 'typeAbbrev': 'Prot', 'uploadDate': '2018-06-26T23:20', 'hasProtocol': True}, {'date': '2018-02-07', 'size': 1264765, 'label': 'Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'SAP_001.pdf', 'typeAbbrev': 'SAP', 'uploadDate': '2019-03-19T04:48', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 85}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2015-09-10', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2019-03', 'completionDateStruct': {'date': '2018-05-21', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2019-09-17', 'studyFirstSubmitDate': '2016-07-26', 'resultsFirstSubmitDate': '2018-06-28', 'studyFirstSubmitQcDate': '2017-11-16', 'lastUpdatePostDateStruct': {'date': '2019-10-01', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2019-08-06', 'studyFirstPostDateStruct': {'date': '2017-11-21', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2019-09-12', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-07-21', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Objective Response Rate(ORR) by International Working Group Criteria', 'timeFrame': '2 years', 'description': 'ORR defined as the percentage of subjects with CR, CRu or PR as Best Overall Response.Evaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (i.e. prior to cycles 6, 8, etc). Unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.The primary analysis will be conducted once all subjects have completed cycle 5 treatment or discontinued before. Study treatment may continue per investigator judgment for a maximum of 24 months.\n\nResponse will be assessed on the basis of clinical, radiological, and pathological criteria. Response will be assessed by independent central review and by the treating investigator. Central review assessors will be blinded to the response assessments by the treating investigator. The primary analysis will be based on response assessed by central review.'}], 'secondaryOutcomes': [{'measure': 'Time to Response (TTR)', 'timeFrame': '2 years', 'description': 'Time to response was measured from first day of treatment to the first date of documented response.'}, {'measure': 'Progression-Free Survival (PFS)', 'timeFrame': '2 years', 'description': 'PFS was measured from treatment day 1 until event or censoring. An event was defined as the earliest of the following: death from any cause or disease progression. Subjects undergoing transplant or any other subsequent therapy prior to documentation of PD was censored at that time. Progression of disease deems as 1. 50% increase from nadir in the SPD of any previously identified abnormal node for PRs or nonresponders, 2.Appearance of any new lesion during or at the end of therapy as per IWC criteria.'}, {'measure': 'Overall Survival (OS)', 'timeFrame': '4 years', 'description': 'OS was measured from treatment day 1 until death or censoring.'}, {'measure': 'Duration of Responses', 'timeFrame': '4 years', 'description': 'Duration of response was measured from first day of documented response to disease progression or death, whatever comes first.'}, {'measure': 'Percentage of Participants With Treatment Emergent Adverse Events', 'timeFrame': '4 years', 'description': 'treatment emergent AE was scheduled to be collected during all subject visits, the data evaluated as clinical significant will be summarized and presented.'}, {'measure': 'Area Under the Curve [AUC] for R-pralatrexate', 'timeFrame': 'Cycle 1 day1，Cycle 1 week 6(Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection)', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Area Under the Curve [AUC] for S-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Steady State Volume of Distribution [Vdss] for R-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week6(Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection)', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Steady State Volume of Distribution [Vdss] for S-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Steady State Clearance [CLss] for R-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Steady State Clearance [CLss] for S-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Maximum Observed Plasma Concentration [Cmax] for R-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Maximum Observed Plasma Concentration [Cmax] for S-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Time of Cmax Observation [Tmax] for R-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Time of Cmax Observation [Tmax] for S-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Terminal Phase Half-life [t1/2Z] for R-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}, {'measure': 'Terminal Phase Half-life [t1/2Z] for S-pralatrexate', 'timeFrame': 'Cycle 1 day 1, Cycle 1 week 6（Pre-injection, end-injection, 30 and 60 minutes, and 3, 5, 8, 12, 18, 24, 48, and 72 hours post-end injection）', 'description': 'The PK endpoints was analysed using the PK population. The overall PK population is defined as all subjects who receive at least one dose of Investigational Medicinal Product (IMP) and have at least one primary PK parameter. Subjects with non-zero baseline concentrations of \\>5% of Cmax for either analyte (R-pralatrexate or S-pralatrexate) will be removed from the PK population.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['FOT12-CN-301', 'PTCL (peripheral T-cell lymphoma)', 'pralatrexate', 'vitamin B12', 'folic acid'], 'conditions': ['Refractory Peripheral T-Cell Lymphoma', 'Relapsed T-Cell Lymphoma']}, 'referencesModule': {'references': [{'pmid': '30904980', 'type': 'DERIVED', 'citation': 'Hong X, Song Y, Huang H, Bai B, Zhang H, Ke X, Shi Y, Zhu J, Lu G, Liebscher S, Cai C. Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. Target Oncol. 2019 Apr;14(2):149-158. doi: 10.1007/s11523-019-00630-y.'}]}, 'descriptionModule': {'briefSummary': 'This is a single arm, open-label, multi-center study designed to demonstrate the efficacy and safety of pralatrexate when administered concurrently with vitamin B12 and folic acid supplementation to patients with relapsed or refractory peripheral T-cell lymphoma(PTCL).', 'detailedDescription': "The primary objective of this study is to confirm the objective response rate (ORR) among Chinese subjects with relapsed or refractory PTCL treated with pralatrexate together with concurrent vitamin B12 and folic acid supplementation\n\nPrimary endpoint is objective Response Rate by International Working Group Criteria\n\nThis study includes 3 phases: Screening, Treatment (pralatrexate) and Follow-up phases.\n\nScreening Phase:\n\nThe screening phase will be up to 28 days duration (depending on availability of lab results).\n\nTreatment (pralatrexate) Phase:\n\nThe start of study treatment (pralatrexate) is defined as the initiation of pralatrexate. Patients will attend the clinic weekly for 6 weeks of a 7-week cycle to receive pralatrexate, and will be examined by the treating physician. One cycle of pralatrexate therapy is 7 weeks in duration and consists of 6 weekly doses of pralatrexate administered via intravenous (IV) push over 3-5 minutes, followed by 1 week of rest.\n\nEvaluation of response must be performed within 7 days prior to the projected first dose of cycle 2-4 and then within 7 days prior to the projected first dose of every even-numbered subsequent cycle (ie, prior to cycles 6, 8, etc.). Although radiological response assessments have been scheduled every 14 weeks, unscheduled radiological response assessments will be performed earlier if clinical progression is suspected.\n\nTreatment with pralatrexate will continue until 24 months of administration, or until documented disease progression; unacceptable adverse event(s) indicating intolerance of the lowest study dose allowed (20 mg/m2/week); omission of 3 sequential doses of pralatrexate due to a treatment-related AE; 3-week lapse between pralatrexate doses; development of an AE, intercurrent illness, condition, or procedural complication that may interfere with the subject's participation; investigator's decision to withdraw the subject; subject withdraws consent; pregnancy of the subject; noncompliance with trial treatment or procedure requirements; or administrative reasons.\n\nFollow-up phase:\n\nAll patients who received at least 1 dose of pralatrexate are to attend the Safety Follow-up Visit \\[30 (± 5) days after the last dose of pralatrexate\\] and the protocol defined procedures and evaluations will be performed.\n\nAfter the Safety Follow-up Visit, Routine Follow-up Visits will be based on standard clinical care. All patients who received at least 1 dose of pralatrexate are to attend Routine Follow-up Visits, which will occur every 3 months (± 2 weeks) for determination of progression of disease, subsequent treatment initiation for T-cell lymphoma and survival after the Safety Follow-up Visit for a total duration of 24 months after the last dose of pralatrexate. The protocol-defined procedures/evaluations should be performed at each Routine Follow-up Visit."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. Subject has histologically/cytologically confirmed PTCL, using the World Health Organization (WHO) disease classification:\n\n 1. PTCL not otherwise specified (NOS)\n 2. Angioimmunoblastic T-cell lymphoma\n 3. Anaplastic large cell lymphoma, ALK+\n 4. Anaplastic large cell lymphoma, ALK-\n 5. Extranodal NK/T-cell lymphoma - nasal type\n 6. Enteropathy-associated T cell lymphoma\n 7. Hepatosplenic T-cell lymphoma\n 8. Subcutaneous panniculitis-like T-cell lymphoma\n 9. Adult T-cell lymphoma/leukemia (human T-cell leukemia virus \\[HTLV\\] 1+)\n 10. Aggressive NK-cell leukemia\n 11. Transformed mycosis fungoides\n2. Subject has to have documented progressive disease (PD) after at least 1 prior systemic treatment.\n3. Subject may not have received an experimental drug or biologic as their only prior therapy. Subject must have clear PD after the last treatment received. Subject should have at least 1 biopsy from initial diagnosis or in the relapsed setting to confirm the diagnosis of PTCL. Subject must have recovered from the toxic effects of prior therapy.\n4. Subjects with an enlarged lymph node or extranodal mass lesion clearly measurable in two perpendicular directions and greater than 1.5 cm maximum diameter on computed tomography performed within 14 days prior to study enrollment.\n5. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2.\n6. At least 18 years of age.\n7. Expected life expectancy ≥ 3 months.\n8. Adequate hematological, hepatic, and renal function as defined by:\n\n * Absolute neutrophil count (ANC) ≥ 1000/uL (or 1\\*109/L), platelet count ≥ 100,000/uL (or 100\\*109/L) (at both screening and within 3 days prior to dosing on cycle 1, day 1)\n * Total bilirubin ≤ 1.5 mg/dL, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 X upper limit of normal (ULN) (AST/ALT \\< 5 X ULN if documented hepatic involvement with lymphoma)\n * Creatinine ≤ 1.5 mg/dL (or 132.6 µmol/L) or a calculated creatinine clearance ≥ 50 mL/min\n9. Women of childbearing potential must have agreed to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 30 days after the last administration of pralatrexate and must have a negative serum pregnancy test within 14 days prior to the first day of study treatment. Subjects who are postmenopausal for at least 1 year (\\> 12 months since last menses) or are surgically sterilized did not require this test.\n10. Men who are not surgically sterile must agree to practice a medically acceptable contraceptive regimen from study treatment initiation until at least 90 days after the last administration of pralatrexate.\n11. Subject gives written informed consent (IC).\n\nExclusion Criteria:\n\n1. Subject has:\n\n 1. Precursor T-cell lymphoma or leukemia\n 2. T-cell prolymphocytic leukemia (T-PLL)\n 3. T-cell large granular lymphocytic leukemia\n 4. Mycosis fungoides, other than transformed mycosis fungoides\n 5. Sézary syndrome\n 6. Primary cutaneous CD30+ T-cell disorders: Lymphoid papulosis and primary cutaneous anaplastic large cell lymphoma\n2. Active concurrent malignancy (except non-melanoma skin cancer or carcinoma in situ of the cervix). If there is a history of prior malignancy, the patient must be disease-free for ≥ 5 years.\n3. Congestive heart failure Class III/IV according to the New York Heart Association's Heart Failure guidelines.\n4. Human immunodeficiency virus (HIV)-positive diagnosis.\n5. Has, or history of, brain metastases or central nervous system (CNS) disease.\n6. Active uncontrolled infection, underlying medical condition including unstable cardiac disease, or other serious illness that would impair the ability of the subject to receive protocol treatment.\n7. Has major surgery within 2 weeks of study entry.\n8. Receipt of any conventional chemotherapy or radiation therapy (RT) within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study treatment or planned use during the course of the study.\n9. Receipt of corticosteroids within 7 days of study treatment, unless subject has been taking a continuous systemic dose of no more than 10 mg/day or equivalent dose of prednisone, or a local or inhaled or intranasal administration at fixed doses for at least 1 month prior to study treatment and tumor shrinkage was not observed.\n10. Use of any investigational drugs, biologics, or devices within 4 weeks prior to study treatment or planned use during the course of the study.\n11. Receipt of anti-tumor antibody therapy within 100 days prior to study treatment.\n12. History of allogeneic hematopoietic stem cell transplantation. Or subjects with a history of autologous hematopoietic stem cell transplantation within 100 days prior to study treatment.\n13. Previous exposure to pralatrexate.\n14. Subject is pregnant or breast-feeding"}, 'identificationModule': {'nctId': 'NCT03349333', 'briefTitle': 'A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL', 'organization': {'class': 'INDUSTRY', 'fullName': 'Mundipharma (China) Pharmaceutical Co. Ltd'}, 'officialTitle': 'A Multi-center, Single Arm, Safety and Efficacy Study of Pralatrexate With Vitamin B12 and Folic Acid Supplementation in Subjects With Relapsed or Refractory Peripheral T-cell Lymphoma', 'orgStudyIdInfo': {'id': 'FOT12-CN-301'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'pralatrexate', 'description': 'Vitamin B12 and folic acid will be taken concurrently with pralatrexate', 'interventionNames': ['Drug: pralatrexate', 'Dietary Supplement: Vitamin B12 and folic acid']}], 'interventions': [{'name': 'pralatrexate', 'type': 'DRUG', 'description': 'Pralatrexate will be administered at a dose of 30 mg/m2/week for 6 weeks followed by 1 week of rest in a 7-week cycle. Pralatrexate administration occurs once a week during week 1 through week 6 of each cycle.', 'armGroupLabels': ['pralatrexate']}, {'name': 'Vitamin B12 and folic acid', 'type': 'DIETARY_SUPPLEMENT', 'description': 'The eligible subjects will receive vitamin supplementation at screening phase, at least 10 days prior to pralatrexate administration on cycle 1, dose 1. Vitamin supplementation will consist of vitamin B12 1 mg intramuscular (IM) q 8-10 weeks and folic acid 1.2mg by mouth (PO) once a day (QD). Once pralatrexate is permanently discontinued, vitamin supplementation should continue at least 1 month after the last pralatrexate dose, or longer at the discretion of the investigator.', 'armGroupLabels': ['pralatrexate']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100142', 'city': 'Beijing', 'country': 'China', 'facility': 'Beijing Cancer Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}], 'overallOfficials': [{'name': 'Victoria YU', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Mundipharma, China'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Mundipharma (China) Pharmaceutical Co. Ltd', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}